Naratriptan Juta

Naratriptan, the active ingredient in Naratriptan Juta, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Naratriptan Juta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan acts on the serotonergic pathway involved in migraine pathophysiology.

Migraine (without aura): provides rapid relief of headache pain and associated symptoms. Migraine (with aura): reduces headache intensity and may alleviate aura‑related discomfort. Acute migraine attacks: shortens the duration of an attack when taken at onset.

Naratriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: sensation of light‑headedness. - Fatigue: feeling unusually tired. - Dry mouth: reduced salivation. - Tingling: paresthesia in extremities. - Drowsiness: increased sleepiness.

Serious or Rare Side Effects: - Chest pain: possible cardiac ischemia. - Severe hypertension: marked increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic drugs. - Anaphylaxis: rare severe allergic reaction. - Cardiac arrhythmia: irregular heart rhythm. - Hepatic dysfunction: abnormal liver enzymes.

When prescribing Naratriptan, clinicians should consider several safety precautions.

Medical history: assess for cardiovascular disease, uncontrolled hypertension, or cerebrovascular disorders. Concomitant medications: review use of other serotonergic agents or triptans. Pregnancy: safety not established; use only if benefit outweighs risk. Driving: may cause drowsiness; advise caution. Alcohol: can increase side‑effect intensity. Store at ambient temperature: keep in the original pack, protect from moisture and light, and keep out of reach of children.

Naratriptan can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - SSRIs, SNRIs, or other serotonergic drugs: potential serotonin syndrome. - Ergotamine derivatives or other triptans: increased risk of vasospasm.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance blood pressure‑lowering effect. - Diuretics: possible additive hypotensive effect. - Oral contraceptives: may alter plasma concentrations. - CYP3A4 inhibitors: may increase Naratriptan levels. - Antihistamines: could potentiate drowsiness.